A laboratory analysis of GW Pharmaceuticals' cannabis samples of Sativex. Image: PA via   Telegraph.co.uk

GW Pharmaceuticals, which makes drugs derived from the cannabis plant, is scaling up its manufacturing capacity ahead of an expected approval of a new treatment for children with life-threatening epilepsy.

Chief executive Justin Gover said production in 2015 had already increased by 20 times and that this was expected to double further in 2016 to meet "significant" commercial demand for Epidiolex, if it is approved by the US Food and Drug Administration.

Some analysts believe the drug could get the green light in early 2017.

Click here to read the complete article

Julia Bradshaw ~ Telegraph.co.uk ~

Recent News Articles

Tuesday March 26

Hemp About To Be Removed From Texas’ Controlled Substances List - Cannabis News

in Law & Crime

by Bruce Kennedy - Editor in Chief

The state of Texas is taking a big step toward legitimizing the use of CBD…

837 hits

Tuesday March 26

Flood of products containing cannabis extract puts FDA in a bind - Cannabis News

in CBD & Hemp

by Bruce Kennedy - Editor in Chief

What might have been an FDA attempt to hit the pause button while it sorts…

1021 hits

Tuesday March 26

Mexican Government Launches Poll To Ask Citizens If Marijuana Should Be Legal - Cannabis News

in World News

by Bruce Kennedy - Editor in Chief

A Mexican cabinet official is asking the country’s citizens whether they support legalizing marijuana—in a…

1131 hits

Tuesday March 26

A Beginners Guide To Reading Marijuana Labels - Cannabis News

in Cannabis News

by Bruce Kennedy - Editor in Chief

The plant has never been more accessible so read up.

1504 hits

Wednesday March 27

Can medicinal cannabis treat the tics in Tourette syndrome? - Cannabis News

in Medical News

by Bruce Kennedy - Editor in Chief

A pioneering clinical trial investigating medicinal cannabis as a potential treatment for people living with…

709 hits